Dec 18 $75 / $70 Bull Put Spread
Sell 1x $75P · Buy 1x $70P · 31d
DexCom (DXCM) trades at $79.32, close to its base-case intrinsic value of $78.25 (-1%). The model starts from $3.13 in expected earnings per share, grows it at 16.1% annually (analyst consensus) decaying to a 4% terminal rate by Year 5, applies a 25.0x exit multiple, and discounts the result back at 10% per year. The stock looks roughly fairly priced under these assumptions — the sliders below show how sensitive that conclusion is to growth and discount-rate changes.
Discounted Cash Flow with Growth Decay Model
Adjust the assumptions below to model different scenarios. The intrinsic value updates in real-time.
Across 19 years of multi-cycle financial history in Surgical & Medical Instruments & Apparatus, only 23.2% of peer companies at >$1B revenue scale (496 historical 5-year windows; industry median CAGR: 5.5%/yr) sustained ≥10%/yr 5-year compound revenue growth (broad >$1B equity base rate: 24.5%).
| Fiscal Year | Annual Revenue | YoY Growth | Operating Income | Operating Margin | Macro Cycle Regime |
|---|---|---|---|---|---|
| FY2025 (2025-12) | $4.66B | +15.6% | $912M | 19.6% | Standard |
| FY2024 (2024-12) | $4.03B | +11.3% | $600M | 14.9% | Standard |
| FY2023 (2023-12) | $3.62B | +24.5% | $598M | 16.5% | Standard |
| FY2022 (2022-12) | $2.91B | +18.8% | $391M | 13.4% | 2022 Rate Shock |
| FY2021 (2021-12) | $2.45B | +27.1% | $266M | 10.9% | Standard |
| FY2020 (2020-12) | $1.93B | +30.5% | $300M | 15.5% | Standard |
| FY2019 (2019-12) | $1.48B | +43.1% | $142M | 9.6% | Standard |
| FY2018 (2018-12) | $1.03B | +43.6% | -$186M | -18.1% | Standard |
| FY2017 (2017-12) | $718M | +25.3% | -$42M | -5.9% | Standard |
| FY2016 (2016-12) | $573M | +42.6% | -$64M | -11.1% | Standard |
| FY2015 (2015-12) | $402M | +55.1% | -$57M | -14.2% | Standard |
| FY2014 (2014-12) | $259M | +62.0% | -$22M | -8.3% | Standard |
| FY2013 (2013-12) | $160M | +60.2% | -$29M | -18.1% | Standard |
| FY2012 (2012-12) | $100M | +30.9% | -$56M | -55.8% | Standard |
| FY2011 (2011-12) | $76M | +57.0% | -$45M | -58.7% | Standard |
| FY2010 (2010-12) | $49M | +63.7% | -$45M | -93.2% | Standard |
| FY2009 (2009-12) | $30M | — | -$46M | -154.4% | 2008–09 Trough Floor |
EPS growth decays from initial rate to terminal rate over the projection period.
| Year | Growth Rate | EPS | Stock Price | Present Value |
|---|
How intrinsic value changes with different growth and discount rate assumptions.
Compare $8,161 for 100 DXCM shares against defined-margin put credit buffers and 5-day directional option spreads.
Sell 1x $75P · Buy 1x $70P · 31d
Buy 1x $85P · Sell 1x $75P · 31d
Buy 1x $80C · Sell 1x $90C · 31d
Growth Decay Model: We project EPS growth that gradually slows from the initial rate to a terminal rate (typically 3-4%, matching long-term GDP growth).
Terminal Value: At the end of the projection period, we apply an exit PE multiple to estimate the future stock price.
Discounting: Future values are discounted back to today using your required rate of return (discount rate).